If you have a gastroenteropancreatic neuroendocrine tumour - often called a GEP-NET - and you live in Pakistan, Bangladesh, or Sri Lanka, you may have found that PRRT (peptide receptor radionuclide therapy) is difficult or impossible to access at home. This article is for the DOTATATE track: GEP-NET patients with somatostatin receptor-positive tumours who are considering travel to India for lutetium Lu-177 dotatate therapy.
India has offered PRRT since 2010. A published review from the Radiation Medicine Centre, Tata Memorial Hospital reports that more than 4,000 therapy cycles were administered to around 1,000 patients at that single centre over one decade - one of the largest single-centre experiences in the world. For patients from neighbouring South Asian countries, India combines that clinical depth with geographic proximity, cultural familiarity, and direct air connections from Dhaka, Colombo, Lahore, and Karachi.
What PRRT Does for GEP-NETs
Lutetium Lu-177 dotatate - sold under the brand name Lutathera - is a type of radioligand therapy. It works by attaching a radioactive molecule to a peptide that seeks out somatostatin receptors on neuroendocrine tumour cells. When the peptide finds those receptors, it delivers targeted radiation directly to the tumour from the inside - sparing much of the surrounding healthy tissue.
The landmark NETTER-1 phase III trial, published in the New England Journal of Medicine, found that lutetium Lu-177 dotatate significantly extended progression-free survival compared with high-dose octreotide in patients with somatostatin receptor-positive midgut NETs. Based on that evidence, the US Food and Drug Administration approved lutetium Lu-177 dotatate for GEP-NETs. The Neuroendocrine Tumor Research Foundation provides a patient-facing overview of nuclear medicine therapies for NETs, including PRRT, for people who are newly learning about this treatment.
The standard course is four cycles, each spaced approximately eight weeks apart. Each cycle involves an intravenous infusion of the therapy alongside an amino acid solution given to help protect the kidneys. After each infusion, most Indian centres keep patients under radiation safety monitoring for 24 hours before discharge.
For a detailed look at what happens when somatostatin analogues stop working and PRRT becomes the next step, the Lutetium Therapy article on PRRT after somatostatin analogue failure in GEP-NET explains the sequencing in plain terms.
Are You Eligible for PRRT?
To be considered for lutetium Lu-177 dotatate therapy, you generally need all of the following:
- A confirmed GEP-NET diagnosis - usually a well-differentiated, lower-grade tumour (grade 1 or grade 2 as recorded on your pathology report)
- A positive Ga-68 DOTATATE PET-CT scan showing that your tumour cells express somatostatin receptors at levels high enough to target
- Adequate kidney function, blood counts, and liver function on recent laboratory tests
- Disease that has progressed or is no longer adequately controlled on somatostatin analogue therapy such as octreotide or lanreotide
The Ga-68 DOTATATE PET-CT scan is the key test. If your tumour does not take up the tracer on that scan, lutetium Lu-177 dotatate is unlikely to reach it either. Not every GEP-NET patient qualifies: higher-grade tumours, poor kidney function, or low somatostatin receptor expression may make PRRT unsuitable. A remote eligibility review before you commit to travel means you find out before booking flights - not after you arrive.
If you want an independent review of whether PRRT is right for your specific case, you can consult the Art of Healing Cancer nuclear-medicine team. They assess DOTATATE-PET images and pathology remotely for international patients and can help clarify your options before you travel.
To understand exactly what your tumour grade means for eligibility, see the Lutetium Therapy article on what your NET pathology grade means for PRRT eligibility.
How Does PRRT Cost Compare: India vs USA vs UK?
| Factor | PRRT in India | PRRT in USA | PRRT in UK (private) |
|---|---|---|---|
| Approx. cost per cycle (USD, 2025) | approx. USD 6,000-10,000 | Substantially higher - request a written quote from your centre | Substantially higher - request a written quote from your centre |
| Approx. full 4-cycle course (USD, 2025) | approx. USD 24,000-40,000 (drug, admissions, amino acid infusions) | Substantially higher; drug alone carries a high wholesale list price in addition to facility and physician fees | Not routinely available on public health systems; private access and cost vary by centre |
| Routine availability | Yes - multiple AERB-approved public and private centres | Yes - FDA-approved since 2018 | Limited - select private oncology centres only |
| Typical wait after eligibility confirmed | Approximately 2-4 weeks from first teleconsultation | Varies; specialist centres may have waiting periods of several weeks to months | Varies; often requires GP referral and specialist review before scheduling |
| Entry for South Asian nationals | Indian medical visa available; direct flights from Dhaka, Colombo, Lahore, Karachi | US visa required; process can take weeks to months | UK visa required; multi-week processing, no direct medical travel corridor |
India cost figures above are sourced from Gleneagles Hospitals' published PRRT cost overview and represent approximate ranges for 2025. US and UK figures were not confirmable from a primary source at time of writing; contact each centre directly for a current written quote. Always ask for an itemised estimate specifying what is included - some centres quote the drug cost only and bill hospital admissions, amino acid infusions, and monitoring tests separately.
For patients from South Asia, India's cost advantage is meaningful on its own. Short flight times and lower travel and accommodation costs compared with North America or Europe make that picture stronger. For a full breakdown of what Indian hospital quotes typically include, the Lutetium Therapy article on Lutathera PRRT cost in India for GEP-NET patients covers this in detail.
Your Step-by-Step Treatment Timeline
The journey from first inquiry to completing all four cycles takes about four to six months. Here is how it works.
- Gather your records (weeks 1-2). Collect your pathology report, Ga-68 DOTATATE PET-CT scans and scan report, recent blood tests covering kidney function, liver function, and a full blood count, plus any prior treatment records. Digital copies on a USB drive or shared cloud folder are accepted by most Indian centres.
- Remote eligibility review (weeks 2-4). Send your scans and records to the Indian nuclear medicine team before committing to travel. Most centres aim to give a preliminary eligibility answer within one to two weeks. This step can prevent an unnecessary trip if your scans show low somatostatin receptor expression or another disqualifying factor.
- Visa application (weeks 3-7). Once eligibility is confirmed and you have a hospital invitation letter, apply for your Indian medical visa. Processing timelines differ by country - see the section below.
- First visit and cycle 1 (approximately 5-7 days in India). Most centres schedule a face-to-face consultation on arrival day, pre-treatment blood tests the following morning, and the infusion shortly after. You stay in hospital for 24 hours after infusion for radiation safety monitoring, then move to nearby accommodation for two to three days before travelling home or to general accommodation.
- Cycles 2, 3, and 4 (every 8 weeks). Each return visit requires approximately four to six days in India. Whether you stay between cycles or fly home is a personal and financial decision explored below.
- Restaging scan (8-12 weeks after the final cycle). A follow-up Ga-68 DOTATATE PET-CT or CT scan checks how the tumour has responded. This can sometimes be arranged in your home country if your local oncologist can interpret the images.
Visa Logistics: Pakistan, Bangladesh, and Sri Lanka
The visa process is the most commonly asked-about practical hurdle. Here is what each nationality faces.
Pakistan
Pakistani nationals cannot apply for an Indian e-Medical Visa online. You must apply for a regular medical visa in person at the Indian Mission - High Commission or Consulate - nearest to you. Required documents typically include your passport, a hospital invitation letter from an accredited Indian hospital, a letter from your treating doctor explaining why treatment in India is needed, proof of financial means, and a completed visa application form. Allow at least three to four weeks. Up to two medical attendants can apply alongside the patient through the same process.
Bangladesh
Bangladeshi patients apply for an Indian Medical Visa through the Indian Mission. A hospital invitation letter is a core requirement. The medical travel route between Bangladesh and India is well-established, with many patients making this journey each year. Direct flights between Dhaka and Kolkata, Chennai, Mumbai, or Delhi can take as little as one to two hours. Allow two to four weeks for visa processing, though timelines can vary.
Sri Lanka
Sri Lankan nationals may apply for an Indian e-Medical Visa online at least four days before planned arrival. The application window opens up to 120 days before your travel date. In many cases, Sri Lankan e-Medical Visas are processed quickly - sometimes within 72 hours - making this a straightforward entry option for medical travel in the region. Up to two e-Medical Attendant Visas can be applied for at the same time. Direct flights from Colombo to Chennai, Mumbai, or Delhi typically take two to three hours.
Regardless of your country, carry your hospital invitation letter, your oncologist's referral letter, and documentation of your diagnosis when you enter India. Border officers may ask to see these at immigration.
Staying in India or Flying Home Between Cycles
With eight weeks between each PRRT cycle, most patients have time to return home after each infusion if they prefer. Many patients from Bangladesh and Sri Lanka - where flights to India are short and relatively affordable - fly home between cycles and return for each treatment. Patients from Pakistan, where the in-person visa process is more involved, sometimes find it simpler to arrange a single longer-stay visa and remain in India throughout the full course.
There is no single medically superior answer. Your nuclear medicine team will advise on radiation safety precautions for travel in the days immediately after each infusion. After that initial precautionary period, long-distance travel is generally permissible for most patients - confirm the specific timeline with your treating team before booking return flights.
If you plan to stay in India between cycles, hospitals in cities such as Chennai, Mumbai, Hyderabad, and Ahmedabad typically have patient liaison teams or lists of nearby accommodation suited to patients and their attendants. Budget guesthouses and mid-range serviced apartments are both available close to most major NET treatment centres. The hospital's international patient services team can usually help you identify suitable options before you arrive.
Long stays away from home can disrupt sleep and increase stress. Talk to your doctor if medical travel is affecting your health. Over-the-counter sleep aids and stress-relief options are available, but ask your medical team before using any new supplements.
What If You Are Not Eligible?
Not everyone with a GEP-NET qualifies for lutetium Lu-177 dotatate. Higher-grade tumours, inadequate somatostatin receptor expression on the Ga-68 DOTATATE PET scan, poor kidney function, or poor overall fitness may mean PRRT is not suitable for your case. A remote eligibility review before you travel means you learn this before booking flights - not after you arrive in India.
If PRRT is not the right option, second-line alternatives for GEP-NETs do exist - including everolimus, temozolomide-based chemotherapy in some tumour subtypes, and in selected cases, clinical trials. The Lutetium Therapy article on GEP-NET second-line therapy when PRRT is not an option outlines what those pathways can look like.
When to Talk to Your Doctor
Speak with your oncologist or nuclear medicine specialist if any of the following apply:
- Your Ga-68 DOTATATE PET scan shows somatostatin receptor-positive disease and your tumour has grown or progressed on somatostatin analogue therapy
- PRRT is not available or is priced out of reach at home and you want to understand whether travel to India is realistic for your situation
- You want a second opinion on whether your scan and pathology support eligibility before committing to travel
- You are unsure how to obtain a hospital invitation letter or how to begin the medical visa process
To start an eligibility review, you can send your records through the Lutetium Therapy contact form. If lutetium Lu-177 dotatate turns out not to be the right fit, the team can also indicate what alternatives may be worth discussing with your oncologist.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Do I need a Ga-68 DOTATATE PET scan before traveling to India for PRRT?
Yes. A Ga-68 DOTATATE PET-CT scan is required to confirm that your tumour expresses somatostatin receptors - the specific target that lutetium Lu-177 dotatate seeks out. If you have not had this scan, some Indian centres can arrange it at the start of your first visit. Having it done before you travel allows for a remote eligibility check and avoids the possibility of making the trip only to find that your tumour does not take up the tracer.
How long do I need to stay in India for each PRRT cycle?
Each treatment visit typically requires five to seven days in India. This includes one to two days of pre-treatment consultations and blood tests, the infusion itself, a 24-hour monitored hospital stay after the infusion, and two to three days in nearby accommodation before you are cleared to travel. Your nuclear medicine team will confirm the exact schedule based on your clinical situation.
Can I fly home between PRRT cycles?
For most patients, yes. The eight-week gap between cycles gives enough time to return home, recover, and travel back for the next treatment. Your nuclear medicine team will advise on radiation safety precautions for travel in the days immediately after each infusion. After that initial period, long-distance travel is generally permissible. Patients from Bangladesh and Sri Lanka - where flights to India are short - often find flying home between cycles practical and affordable.
How much does a full PRRT course in India cost?
Approximate costs for a four-cycle lutetium Lu-177 dotatate course at Indian centres are typically cited in published hospital ranges at around USD 24,000 to USD 40,000. This usually covers the drug, hospital admissions for each cycle, amino acid infusions given alongside the therapy, and routine monitoring blood tests. Costs vary by centre and by your specific clinical requirements. Always request a written, itemised quote before you commit to travel.
Is PRRT available in Pakistan, Bangladesh, or Sri Lanka?
As of 2025, lutetium Lu-177 dotatate PRRT is not widely available as a routine clinical service in Pakistan, Bangladesh, or Sri Lanka. A small number of academic centres in these countries may have limited capability, but access is not consistent. India has offered PRRT since 2010 and has treated thousands of patients at multiple approved centres, making it the closest high-volume option for patients in the region.
Can I bring a family member as a medical attendant?
Yes. India's medical visa rules allow up to two medical attendants to accompany a patient. The attendant visa application follows the same process as the patient's medical visa and requires the hospital invitation letter confirming the expected duration of treatment. Your hospital's international patient services team can usually help prepare the invitation letter for both the patient and attendants before you apply.
